Trials / Completed
CompletedNCT01382147
Evaluation of "Dose-dense Therapy" by S-HAM in Comparison to Conventionally Timed Double Induction in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (Sequential High Dose Cytosine Arabinoside and Mitoxantrone) Versus Standard Double Induction for Initial Chemotherapy of Adult Patients With Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 396 (actual)
- Sponsor
- Prof. Dr. Wolfgang Hiddemann · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation weather early chemotherapy attempts for remission induction can improve the results of patients with Acute Myeloid Leukemia (AML), as compared to the standard group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ara-C, Mitoxantrone, Daunorubicin, Thioguanin | Chemotherapy |
Timeline
- Start date
- 2009-07-01
- Primary completion
- 2012-08-01
- Completion
- 2017-07-05
- First posted
- 2011-06-27
- Last updated
- 2017-12-06
Locations
32 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01382147. Inclusion in this directory is not an endorsement.